Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $40

Benzinga · 01/13 16:08
Oppenheimer analyst Jay Olson maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $60 to $40.